

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 July 2019

ERRATUM

This Erratum corrects the DPMQ for 11713L in the 1 July 2019 Schedule of Pharmaceutical Benefits as detailed below.

▪ PHENELZINE

Caution This drug is an irreversible monoamine oxidase inhibitor.

Restricted benefit

Depression

Clinical criteria:

- The treatment must be for when all other anti-depressant therapy has failed; OR
- The treatment must be for when all other anti-depressant therapy is inappropriate.

phenelzine 15 mg tablet, 60

11713L	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
	1.7	1	..	*114.87	40.30	^a Nardil [LM]

phenelzine 15 mg tablet, 100

2856H	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
	1	1	..	80.65	40.30	^a Nardil [LM]